EAMS, Raxone and the MHRA

Last week our Director of Campaigns & Strategy, Peter Duffy, attended a meeting at The Medicines and Healthcare products Regulatory Agency (MHRA), as part of the Patient Group Consultative Forum.

One of the key topics discussed was the Early Access to Medicines Scheme (EAMS) and patient involvement. The Duchenne treatment Raxone is part of this scheme, which means that patients with Duchenne, who meet the necessary criteria, may access the drug while it is awaiting approval.

Peter explains EAMS, the MHRA and Raxone in an easy to understand way.

If you have any questions or you would like Peter to answer, please get in touch peter@actionduchenne.org or call 020 7250 8240.